<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>
<channel>
	<title>Medical Product Guide&#187; Pharmaceutical products</title>
	<atom:link href="http://blog.medicalproductguide.com/category/pharmaceutical/feed/" rel="self" type="application/rss+xml" />
	<link>http://blog.medicalproductguide.com</link>
	<description>A comprehensive guide to medical products for medical professionals</description>
	<lastBuildDate>Mon, 20 Jun 2011 12:36:09 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.3</generator>
		<item>
		<title>10 Ways to Prevent Prescription Errors</title>
		<link>http://blog.medicalproductguide.com/2010/11/15/10-ways-prevent-prescription-errors/</link>
		<comments>http://blog.medicalproductguide.com/2010/11/15/10-ways-prevent-prescription-errors/#comments</comments>
		<pubDate>Mon, 15 Nov 2010 16:29:36 +0000</pubDate>
		<dc:creator>Jim Marino</dc:creator>
				<category><![CDATA[Pharmaceutical products]]></category>
		<guid isPermaLink="false">http://www.medicalproductguide.com/blog/?p=570</guid>
		<description><![CDATA[by Rachel Davis Medical errors happen more often than we realize they do; the numbers are staggering – according to information from the Institute of Medicine, between 44,000 and 98,000 deaths and around 1,000,000 injuries occur in the U.S every year due to medical errors. Most of them are preventable, especially prescription errors that result [...]]]></description>
			<content:encoded><![CDATA[<p><strong>by Rachel Davis</strong></p>
<p>Medical errors happen more often than we realize they do; the numbers are staggering – according to information from the Institute of Medicine, between 44,000 and 98,000 deaths and around 1,000,000 injuries occur in the U.S every year due to medical errors. Most of them are preventable, especially prescription errors that result in the wrong medication or the wrong dosage being given to patients. Prescription errors happen for a variety of reasons, such pharmacist error, assistant error and oftentimes patient error. Physicians wanting to help others who are allowed to write prescriptions (like physician assistants and a few nurse practitioners) suggest the following ways to reduce all variety of errors by:</p>
<ol>
<li>Taking extra care to write the prescriptions in a readable manner.</li>
<li>Using electronic prescription entry devices or preprinted prescriptions.</li>
<li>Writing prescriptions without using short forms, abbreviations or codes for the names of drugs so that pharmacist confusion or assumption does not lead to errors.</li>
<li>Setting policies in place where nurses or assistants check the prescription for errors before passing it on to the patient.</li>
<li>Ensuring that the patient has understood the prescription and knows when, how, and for how long to take the drugs.</li>
<li>Prescribing small doses of drugs that could be lethal if taken in large quantities and monitoring their usage.</li>
<li>Marking your name clearly on prescription pads that have the names of multiple physicians so that it is clearly visible and pharmacists know who to call when they need clarification.</li>
<li>Providing simplified dosage instructions understandable to the patient and pharmacist.</li>
<li>Using technology that allows you to send prescriptions directly to the pharmacist so that handwriting errors are prevented.</li>
<li>Adding additional information that is useful to the patient – like things to avoid doing while on certain drugs or why you have prescribed certain drugs. This prevents side-effects and misuse of drugs</li>
</ol>
<p>A prescription is the most important aspect of medical care since it is based on the assessment of the patient’s condition and diagnosis of the illness, and is meant to effect the cure or provide therapeutic benefits. So when prescription errors occur, the very purpose of medical treatment is negated.</p>
<p><strong>By-line</strong>:<br />
This guest post is contributed by <strong>Rachel Davis</strong>, she writes on the topic of <a href="http://radiologydegree.com/">Radiology degree</a>. She welcomes your comments  below.</p>
]]></content:encoded>
			<wfw:commentRss>http://blog.medicalproductguide.com/2010/11/15/10-ways-prevent-prescription-errors/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Covidien Announces The Launch Of The Puritan Bennett(TM) 560 Portable Ventilator In Europe</title>
		<link>http://blog.medicalproductguide.com/2010/09/29/covidien-announces-launch-puritan-bennetttm-560-portable-ventilator-europe/</link>
		<comments>http://blog.medicalproductguide.com/2010/09/29/covidien-announces-launch-puritan-bennetttm-560-portable-ventilator-europe/#comments</comments>
		<pubDate>Wed, 29 Sep 2010 10:46:40 +0000</pubDate>
		<dc:creator>Jim Marino</dc:creator>
				<category><![CDATA[Asthma]]></category>
		<category><![CDATA[Diagnostics products]]></category>
		<category><![CDATA[Medical device market]]></category>
		<category><![CDATA[Covidien]]></category>
		<category><![CDATA[mobile respiratory support]]></category>
		<category><![CDATA[pediatric patients]]></category>
		<category><![CDATA[Puritan Bennett™ 560]]></category>
		<category><![CDATA[ventilator]]></category>
		<guid isPermaLink="false">http://www.medicalproductguide.com/blog/?p=562</guid>
		<description><![CDATA[Covidien announced that the Puritan Bennett™ 560 ventilator is now available in Europe. The Puritan Bennett 560 ventilator is compact and portable, weighing just 4.5 kg. This lightweight device provides mobile respiratory support, enabling ventilated adult and pediatric patients to pursue regular activities with peace of mind. The Puritan Bennett 560 ventilator is designed for [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://blog.medicalproductguide.com/files/2010/09/Covidien.png"><img class="alignright size-full wp-image-561" style="margin: 5px" src="http://blog.medicalproductguide.com/files/2010/09/Covidien.png" border="0" alt="" width="200" height="45" /></a>Covidien announced that the Puritan Bennett™ 560 ventilator is now available in Europe. The Puritan Bennett 560 ventilator is compact and portable, weighing just 4.5 kg. This lightweight device provides mobile respiratory support, enabling ventilated adult and pediatric patients to pursue regular activities with peace of mind. The Puritan Bennett 560 ventilator is designed for patient comfort, safety and maneuverability.</p>
<p>Read the full story <a href="http://www.medicalnewstoday.com/articles/202440.php" target="_blank">here</a></p>
]]></content:encoded>
			<wfw:commentRss>http://blog.medicalproductguide.com/2010/09/29/covidien-announces-launch-puritan-bennetttm-560-portable-ventilator-europe/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Step Towards A New Therapy For Chronic Bowel Disease</title>
		<link>http://blog.medicalproductguide.com/2010/07/28/step-therapy-chronic-bowel-disease/</link>
		<comments>http://blog.medicalproductguide.com/2010/07/28/step-therapy-chronic-bowel-disease/#comments</comments>
		<pubDate>Wed, 28 Jul 2010 06:20:53 +0000</pubDate>
		<dc:creator>Jim Marino</dc:creator>
				<category><![CDATA[Aesthetics]]></category>
		<category><![CDATA[Anti-inflammatory]]></category>
		<guid isPermaLink="false">http://www.medicalproductguide.com/blog/?p=495</guid>
		<description><![CDATA[Scientists associated with VIB (Flanders Institute for Biotechnology) and Ghent University (UGent) have discovered that A20 protein plays an important protective role in diseases associated with chronic bowel inflammation. This makes A20 into a promising therapeutic target for the development of new anti-inflammatory drugs. The NF-kB protein plays a critical role in the inflammatory response [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://blog.medicalproductguide.com/files/2010/07/VIB1.png"><img class="alignleft size-full wp-image-499" style="margin: 5px" src="http://blog.medicalproductguide.com/files/2010/07/VIB1.png" border="0" alt="" width="200" height="200" /></a>Scientists associated with VIB (Flanders Institute for Biotechnology) and Ghent University (UGent) have discovered that A20 protein plays an important protective role in diseases associated with chronic bowel inflammation. This makes A20 into a promising therapeutic target for the development of new anti-inflammatory drugs. The NF-kB protein plays a critical role in the inflammatory response and is activated by e.g. TNF, which is produced by the white blood cells.</p>
<p>Read the full story <a href="http://www.medicalnewstoday.com/articles/193905.php" target="_blank">here</a></p>
]]></content:encoded>
			<wfw:commentRss>http://blog.medicalproductguide.com/2010/07/28/step-therapy-chronic-bowel-disease/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Mylan Receives FDA Approval For Nabumetone</title>
		<link>http://blog.medicalproductguide.com/2010/07/16/mylan-receives-fda-approval-nabumetone/</link>
		<comments>http://blog.medicalproductguide.com/2010/07/16/mylan-receives-fda-approval-nabumetone/#comments</comments>
		<pubDate>Fri, 16 Jul 2010 09:09:23 +0000</pubDate>
		<dc:creator>Jim Marino</dc:creator>
				<category><![CDATA[Company news]]></category>
		<category><![CDATA[FDA approvals]]></category>
		<category><![CDATA[Orthopedic products]]></category>
		<category><![CDATA[Osteoporosis]]></category>
		<category><![CDATA[Pharmaceutical products]]></category>
		<category><![CDATA[arthritis]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[inflammation]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Nabumetone]]></category>
		<category><![CDATA[osteoarthritis]]></category>
		<category><![CDATA[rheumatoid arthritis]]></category>
		<guid isPermaLink="false">http://www.medicalproductguide.com/blog/?p=459</guid>
		<description><![CDATA[Mylan Inc. received the FDA approved for its generic version of the osteoarthritis and rheumatoid arthritis drug Nabumetone. The FDA approval allows Mylan to sell 500 milligram and 750 milligram tablets of Nabumetone. It is a nonsteroidal anti-inflammatory drug, which is a popular type of arthritis and inflammation treatment. Read the full story here.]]></description>
			<content:encoded><![CDATA[<p><a href="http://blog.medicalproductguide.com/files/2010/07/Medtronic.png"><img class="alignright size-full wp-image-460" src="http://blog.medicalproductguide.com/files/2010/07/Medtronic.png" alt="" width="200" height="45" /></a>Mylan Inc. received the FDA approved for its generic version of the osteoarthritis and rheumatoid arthritis drug Nabumetone. The FDA approval allows Mylan to sell 500 milligram and 750 milligram tablets of Nabumetone. It is a nonsteroidal anti-inflammatory drug, which is a popular type of arthritis and inflammation treatment.</p>
<p>Read the full story <a href="http://www.businessweek.com/ap/financialnews/D9GV1R080.htm">here</a>.</p>
]]></content:encoded>
			<wfw:commentRss>http://blog.medicalproductguide.com/2010/07/16/mylan-receives-fda-approval-nabumetone/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Approves Daytrana for ADHD</title>
		<link>http://blog.medicalproductguide.com/2010/07/09/fda-approves-daytrana-adhd/</link>
		<comments>http://blog.medicalproductguide.com/2010/07/09/fda-approves-daytrana-adhd/#comments</comments>
		<pubDate>Fri, 09 Jul 2010 19:19:32 +0000</pubDate>
		<dc:creator>Jim Marino</dc:creator>
				<category><![CDATA[Company news]]></category>
		<category><![CDATA[FDA approvals]]></category>
		<category><![CDATA[Neurology Products]]></category>
		<category><![CDATA[Pharmaceutical products]]></category>
		<category><![CDATA[ADHD]]></category>
		<category><![CDATA[Daytrana]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[methylphenidate patch]]></category>
		<guid isPermaLink="false">http://www.medicalproductguide.com/blog/?p=457</guid>
		<description><![CDATA[The FDA has approved an expanded age range for a methylphenidate transdermal system (Daytrana; Shire, under license from Noven Pharmaceuticals, Inc) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adolescents aged 13 to 17 years. Previously approved for use in children aged 6 to 12 years, the methylphenidate patch is indicated as an integral part [...]]]></description>
			<content:encoded><![CDATA[<p>The FDA has approved an expanded age range for a methylphenidate transdermal system (Daytrana; Shire, under license from Noven Pharmaceuticals, Inc) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adolescents aged 13 to 17 years. Previously approved for use in children aged 6 to 12 years, the methylphenidate patch is indicated as an integral part of a total treatment program that may include psychological, educational, and social measures.</p>
]]></content:encoded>
			<wfw:commentRss>http://blog.medicalproductguide.com/2010/07/09/fda-approves-daytrana-adhd/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Roxane Receives FDA Approval For Anastrozole Tablets</title>
		<link>http://blog.medicalproductguide.com/2010/07/09/roxane-receives-fda-approval-anastrozole-tablets/</link>
		<comments>http://blog.medicalproductguide.com/2010/07/09/roxane-receives-fda-approval-anastrozole-tablets/#comments</comments>
		<pubDate>Fri, 09 Jul 2010 19:14:49 +0000</pubDate>
		<dc:creator>Jim Marino</dc:creator>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[FDA approvals]]></category>
		<category><![CDATA[Oncology products]]></category>
		<category><![CDATA[Pharmaceutical products]]></category>
		<category><![CDATA[anastrozole]]></category>
		<category><![CDATA[Anastrozole Tablets]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[ARIMIDEX]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Roxane Laboratories]]></category>
		<guid isPermaLink="false">http://www.medicalproductguide.com/blog/?p=454</guid>
		<description><![CDATA[Roxane Laboratories has received approval of its Abbreviated New Drug Application (ANDA) for Anastrozole Tablets, 1mg by the FDA. The product is available in bottles of 30 for immediate shipment to wholesalers and pharmacies across the US. Roxane Laboratories&#8217; Anastrozole Tablets are AB rated to ARIMIDEX® (anastrozole) tablets.]]></description>
			<content:encoded><![CDATA[<p>Roxane Laboratories has received approval of its Abbreviated New Drug Application (ANDA) for Anastrozole Tablets, 1mg by the FDA. The product is available in bottles of 30 for immediate shipment to wholesalers and pharmacies across the US. Roxane Laboratories&#8217; Anastrozole Tablets are AB rated to ARIMIDEX® (anastrozole) tablets.</p>
]]></content:encoded>
			<wfw:commentRss>http://blog.medicalproductguide.com/2010/07/09/roxane-receives-fda-approval-anastrozole-tablets/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Novel Brain-based Computational Model Of How Parkinson&#8217;s Disease And Dopamine Medications Affect Learning And Attention</title>
		<link>http://blog.medicalproductguide.com/2010/01/25/brainbased-computational-model-parkinsons-disease-dopamine-medications-affect-learning-attention/</link>
		<comments>http://blog.medicalproductguide.com/2010/01/25/brainbased-computational-model-parkinsons-disease-dopamine-medications-affect-learning-attention/#comments</comments>
		<pubDate>Mon, 25 Jan 2010 06:36:35 +0000</pubDate>
		<dc:creator>Jim Marino</dc:creator>
				<category><![CDATA[Parkinson's]]></category>
		<category><![CDATA[Journal of Cognitive Neuroscience]]></category>
		<category><![CDATA[Parkinson's disease]]></category>
		<category><![CDATA[Rutgers University]]></category>
		<guid isPermaLink="false">http://www.medicalproductguide.com/blog/?p=420</guid>
		<description><![CDATA[A new brain-based computational model is helping to understand how Parkinson&#8217;s disease and dopamine medications &#8211; used to treat motor symptoms caused by the disease &#8211; can affect learning and attention. As reported in a forthcoming article in the Journal of Cognitive Neuroscience, a new computational model, at the Center for Molecular and Behavioral Neuroscience [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://blog.medicalproductguide.com/files/2010/01/Journal-of-Cognitive-Neuroscience.png"><img class="alignleft size-full wp-image-421" style="margin: 5px" src="http://blog.medicalproductguide.com/files/2010/01/Journal-of-Cognitive-Neuroscience.png" border="0" alt="Journal of Cognitive Neuroscience" width="200" height="67" /></a>A new brain-based computational model is helping to understand how Parkinson&#8217;s disease and dopamine medications &#8211; used to treat motor symptoms caused by the disease &#8211; can affect learning and attention. As reported in a forthcoming article in the Journal of Cognitive Neuroscience<em>,</em> a new computational model, at the Center for Molecular and Behavioral Neuroscience at Rutgers University, Newark, has shown how Parkinson&#8217;s disease affects attentional performance during learning.</p>
<p>For the full story, <a href="http://www.medicalnewstoday.com/articles/176727.php" target="_blank">Click Here</a></p>
]]></content:encoded>
			<wfw:commentRss>http://blog.medicalproductguide.com/2010/01/25/brainbased-computational-model-parkinsons-disease-dopamine-medications-affect-learning-attention/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TetraLogic Pharmaceuticals Initiates Phase 1 Clinical Trial Of TL32711 In Patients With Refractory Solid Tumors Or Lymphoma</title>
		<link>http://blog.medicalproductguide.com/2010/01/18/tetralogic-pharmaceuticals-initiates-phase-1-clinical-trial-tl32711-patients-refractory-solid-tumors-lymphoma/</link>
		<comments>http://blog.medicalproductguide.com/2010/01/18/tetralogic-pharmaceuticals-initiates-phase-1-clinical-trial-tl32711-patients-refractory-solid-tumors-lymphoma/#comments</comments>
		<pubDate>Mon, 18 Jan 2010 15:30:57 +0000</pubDate>
		<dc:creator>Jim Marino</dc:creator>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Oncology products]]></category>
		<category><![CDATA[selective SMAC mimetic]]></category>
		<category><![CDATA[TetraLogic Pharmaceuticals]]></category>
		<category><![CDATA[TL32711]]></category>
		<guid isPermaLink="false">http://www.medicalproductguide.com/blog/?p=416</guid>
		<description><![CDATA[TetraLogic Pharmaceuticals announced that the Company has completed dosing of the first cohort in a Phase 1 clinical trial of its selective SMAC mimetic, TL32711. The Phase 1 trial is an open-label, dose-escalation study evaluating the safety and tolerability of TL32711 in adults with solid tumors or lymphoma refractory to standard therapies. The study will [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://blog.medicalproductguide.com/files/2010/01/TetraLogic-Pharmaceuticals.png"><img class="alignright size-full wp-image-417" style="margin: 5px" src="http://blog.medicalproductguide.com/files/2010/01/TetraLogic-Pharmaceuticals.png" border="0" alt="TetraLogic Pharmaceuticals" width="200" height="121" /></a>TetraLogic Pharmaceuticals announced that the Company has completed dosing of the first cohort in a Phase 1 clinical trial of its selective SMAC mimetic, TL32711. The Phase 1 trial is an open-label, dose-escalation study evaluating the safety and tolerability of TL32711 in adults with solid tumors or lymphoma refractory to standard therapies. The study will also assess the pharmacokinetics, pharmacodynamics and anti-tumor activity of TL32711.</p>
<p>For the full story, <a href="http://www.medicalnewstoday.com/articles/175591.php" target="_blank">Click Here</a></p>
]]></content:encoded>
			<wfw:commentRss>http://blog.medicalproductguide.com/2010/01/18/tetralogic-pharmaceuticals-initiates-phase-1-clinical-trial-tl32711-patients-refractory-solid-tumors-lymphoma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Switching To Letrozole Helps Breast Cancer Patients With Anastrozole-Related Rheumatologic Symptoms</title>
		<link>http://blog.medicalproductguide.com/2010/01/04/switching-letrozole-helps-breast-cancer-patients-anastrozolerelated-rheumatologic-symptoms/</link>
		<comments>http://blog.medicalproductguide.com/2010/01/04/switching-letrozole-helps-breast-cancer-patients-anastrozolerelated-rheumatologic-symptoms/#comments</comments>
		<pubDate>Mon, 04 Jan 2010 11:56:17 +0000</pubDate>
		<dc:creator>Jim Marino</dc:creator>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[anastrozole]]></category>
		<category><![CDATA[breast cancer]]></category>
		<category><![CDATA[Postmenopausal]]></category>
		<category><![CDATA[SABCS]]></category>
		<guid isPermaLink="false">http://www.medicalproductguide.com/blog/?p=391</guid>
		<description><![CDATA[Postmenopausal women with hormone receptor-positive (HR+) breast cancer who develop arthralgia and/or myalgia (A/M) while being treated with anastrozole may want to consider a switch to letrozole therapy, researchers said at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS). Women who experienced greater than equal to grade 2 A/M while receiving anastrozole and switched [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://blog.medicalproductguide.com/files/2010/01/Annual-San-Antonio-Breast-Cancer-Symposium3.png"><img class="alignright size-full wp-image-399" style="margin: 5px" src="http://blog.medicalproductguide.com/files/2010/01/Annual-San-Antonio-Breast-Cancer-Symposium3.png" border="0" alt="Annual San Antonio Breast Cancer Symposium" width="200" height="117" /></a>Postmenopausal women with hormone receptor-positive (HR+) breast cancer who develop arthralgia and/or myalgia (A/M) while being treated with anastrozole may want to consider a switch to letrozole therapy, researchers said at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS). Women who experienced greater than equal to grade 2 A/M while receiving anastrozole and switched to letrozole developed significantly less A/M and had an improved quality of life compared with baseline.</p>
<p>For the full story, <a href="http://www.medicalnewstoday.com/articles/174943.php" target="_blank">Click Here</a></p>
]]></content:encoded>
			<wfw:commentRss>http://blog.medicalproductguide.com/2010/01/04/switching-letrozole-helps-breast-cancer-patients-anastrozolerelated-rheumatologic-symptoms/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>CleveMed Receives ISO 13485, CE Mark, Canadian Certificate Approval</title>
		<link>http://blog.medicalproductguide.com/2009/11/23/clevemed-receives-iso-13485-ce-mark-canadian-certificate-approval/</link>
		<comments>http://blog.medicalproductguide.com/2009/11/23/clevemed-receives-iso-13485-ce-mark-canadian-certificate-approval/#comments</comments>
		<pubDate>Mon, 23 Nov 2009 11:16:42 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[CE Mark]]></category>
		<category><![CDATA[Parkinson's]]></category>
		<category><![CDATA[BSI Management Systems America Inc]]></category>
		<category><![CDATA[CleveMed]]></category>
		<category><![CDATA[CMDCAS]]></category>
		<category><![CDATA[ISO 13485 certification]]></category>
		<category><![CDATA[Parkinson’s disease]]></category>
		<category><![CDATA[sleep disorders]]></category>
		<guid isPermaLink="false">http://www.medicalproductguide.com/blog/?p=365</guid>
		<description><![CDATA[CleveMed has received ISO 13485 certification issued by BSI Management Systems America Inc. CleveMed has also received the CE Mark and CMDCAS allowing its products to be distributed to the large European and the Canadian markets which will strengthen its worldwide market presence. CleveMed designs and manufactures a number of telemetry-based patient monitors for sleep [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://blog.medicalproductguide.com/files/2009/11/CleveMed.png"><img class="alignright size-full wp-image-366" style="margin: 5px" src="http://blog.medicalproductguide.com/files/2009/11/CleveMed.png" border="0" alt="CleveMed" width="200" height="146" /></a>CleveMed has received ISO 13485 certification issued by BSI Management Systems America Inc. CleveMed has also received the CE Mark and CMDCAS allowing its products to be distributed to the large European and the Canadian markets which will strengthen its worldwide market presence. CleveMed designs and manufactures a number of telemetry-based patient monitors for sleep disorders such as sleep apnea and movement disorders including Parkinson’s disease.</p>
]]></content:encoded>
			<wfw:commentRss>http://blog.medicalproductguide.com/2009/11/23/clevemed-receives-iso-13485-ce-mark-canadian-certificate-approval/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

<!-- Performance optimized by W3 Total Cache. Learn more: http://www.w3-edge.com/wordpress-plugins/

Served from: blog.medicalproductguide.com @ 2012-02-07 11:52:39 -->
